Osagrand (Ibandronic Acid)

Ibandronic acid, the active ingredient in Osagrand, is a bisphosphonate presented as a oral tablet for systemic use. It treats osteoporosis and other bone‑loss conditions in post‑menopausal women and men at risk of fracture.

GNH USA supplies Osagrand as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osagrand is a bisphosphonate that acts on bone‑remodelling pathways to reduce skeletal complications. - Osteoporosis: Improves bone mineral density and reduces risk of vertebral and hip fractures. - Paget’s disease of bone: Helps control abnormal bone turnover. - Hypercalcaemia of malignancy: Lowers serum calcium levels associated with cancer‑related bone resorption. - Glucocorticoid‑induced bone loss: Mitains           - High‑             ",

"mechanism": "Ibandronate binds to hydroxy‑apatite crystals in bone, where it is internalised by osteoclasts during resorption. Once inside the cell, it inhibits farnesyl‑pyrophosphate synthase in the mevalonate pathway, disrupting protein prenylation and leading to osteoclast apoptosis, thereby reducing bone resorption and turnover.",

"effects": "Adverse reactions to ibandronate are reported across a range of .

Common Side Effects: -   ");

Serious or .

",

"precautions": "The .

"",

"interactions": "",

"metatitle": "Osagr4 ",

"metadesc": "",

"keywords": "",

"faqs": [ { "q": "", "a": "" } ],

"schema_jsonld": {} }